Sponsor:
4D Molecular Therapeutics
Code:
NCT07064759
Conditions
Neovascular Age-Related Macular Degeneration (nAMD)
Eligibility Criteria
Sex: All
Age: 50+
Healthy Volunteers: Not accepted
Interventions
4D-150 IVT (3E10 vg/eye)
EYLEA® (aflibercept) Injection 2 mg (0.05mL)
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2026-04-29. This information was provided to ClinicalTrials.gov by 4D Molecular Therapeutics on 2026-04-16.